Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Regencell Bioscience Holdings Limited (RGC)

21.6701   -0.35 (-1.59%) 05-30 10:20
Open: 21.8 Pre. Close: 22.02
High: 21.8 Low: 21.6701
Volume: 857 Market Cap: 282(M)

Technical analysis

as of: 2023-05-31 10:48:54 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 31.75     One year: 36.55
Support: Support1: 20.54    Support2: 17.08
Resistance: Resistance1: 27.18    Resistance2: 31.29
Pivot: 23.89
Moving Average: MA(5): 22.55     MA(20): 24.57
MA(100): 27.14     MA(250): 30.07
MACD: MACD(12,26): -1.2     Signal(9): -0.9
Stochastic oscillator: %K(14,3): 16.3     %D(3): 15.3
RSI: RSI(14): 33.8
52-week: High: 48.29  Low: 20.54
Average Vol(K): 3-Month: 1 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RGC ] has closed above bottom band by 7.5%. Bollinger Bands are 41.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.98 - 23.09 23.09 - 23.2
Low: 20.24 - 20.37 20.37 - 20.49
Close: 20.3 - 20.51 20.51 - 20.71

Company Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Headline News

Sun, 28 May 2023
CEO Yat-Gai Au, Regencell Bioscience Holdings Limited's (NASDAQ:RGC) largest shareholder sees value of holdings go down 10% after recent drop - Simply Wall St

Mon, 03 Apr 2023
Anyone, Anywhere, You Can Make A Difference! - ValueWalk

Wed, 16 Nov 2022
Regencell Bioscience Holdings Limited's (NASDAQ:RGC) CEO Yat-Gai Au is the most upbeat insider, and their holdings increased by 15% last week - Simply Wall St

Tue, 15 Nov 2022
How Can Healthcare And Alternative Medicine Safely Adopt Artificial ... - Entrepreneur

Mon, 12 Sep 2022
Regencell Bioscience's Standardized Formulae Are Shown to ... - Business Wire

Fri, 01 Jul 2022
Game-Stop Or Game-On? RGC Has It All And Twice More - ValueWalk

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 13 (M)
Shares Float 1 (M)
% Held by Insiders 88.7 (%)
% Held by Institutions 0 (%)
Shares Short 4 (K)
Shares Short P.Month 4 (K)

Stock Financials

EPS -0.59
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.3
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -51.9
Return on Equity (ttm) -116.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.58
Qtrly Earnings Growth 0
Operating Cash Flow -5 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -36.73
PEG Ratio 0
Price to Book value 16.54
Price to Sales 0
Price to Cash Flow -53.5

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.